Welcome to our dedicated page for Kineta news (Ticker: $KA), a resource for investors and traders seeking the latest updates and insights on Kineta stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Kineta's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Kineta's position in the market.
Rhea-AI Summary
Kineta, Inc. provides an update on the VISTA-101 Phase 1/2 clinical trial evaluating KVA12123 in patients with advanced solid tumors. Positive findings include stable disease in monotherapy and combination cohorts, favorable safety profile, and no dose-limiting toxicities. The company is suspending new patient enrollment due to funding issues.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.37%
Tags
-
Rhea-AI Summary
Kineta, Inc. reports stable disease in VISTA-101 trial, explores strategic alternatives after restructuring. Financial highlights show decreased cash position.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.76%
Tags
-
Rhea-AI Summary
Kineta, Inc. (KA) reports positive clinical trial results for KVA12123 in oncology, showing stable disease in monotherapy and combination cohorts with no dose-limiting toxicities. The company is exploring strategic alternatives to maximize shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.29%
Tags
Rhea-AI Summary
Kineta, Inc. (Nasdaq: KA) announces a significant corporate restructuring to reduce expenses and preserve cash, including a workforce reduction and termination of enrollment in a clinical trial. The company is exploring strategic alternatives to maximize shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-63.72%
Tags
-
Rhea-AI Summary
Kineta, Inc. (Nasdaq: KA) announces the presentation of new preclinical data on KVA12123, its anti-VISTA antibody, at the AACR Blood Cancer Discovery Symposium. The data focuses on treating Acute Myeloid Leukemia, with the poster presentation by Thierry Guillaudeux, Ph.D., Chief Scientific Officer. The event will take place on March 4-6, 2024, in Boston, Massachusetts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
-
Rhea-AI Summary
Kineta, Inc. (KA) announces its participation in upcoming investors conferences to present its novel immunotherapies in oncology. The Company will attend BIO CEO and Investor Conference, 10th Annual Immuno-Oncology 360 Conference, and Opal Group Family Office Winter Forum for presentations and 1:1 meetings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.96%
Tags
Rhea-AI Summary
Kineta, Inc. (KA) will participate in a virtual H.C. Wainwright @Home Fireside Chat Series on February 13, 2024, to present recent clinical results of KVA12123, the company’s VISTA blocking immunotherapy for advanced solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.57%
Tags
-
Rhea-AI Summary
Kineta, Inc. announced that KVA12123, its novel VISTA blocking immunotherapy, has shown promising results in the VISTA-101 Phase 1/2 clinical trial. The drug cleared the first four monotherapy dose levels and the first cohort in combination with Merck’s anti-PD-1 therapy, KEYTRUDA, with no dose limiting toxicities. The safety profile of KVA12123 supports advancing to higher doses in the monotherapy and combination cohorts of the study. The drug demonstrated dose proportional induction of pro-inflammatory biomarkers required for strong anti-tumor activity, and the clinical study is progressing on time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.35%
Tags
-
Rhea-AI Summary
Kineta, Inc. (Nasdaq: KA) to participate in the 13th Annual LifeSci Partners Corporate Access Event, showcasing potential growth in 2024 with significant progress on the clinical development of KVA12123, a novel VISTA immunotherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8%
Tags
Rhea-AI Summary
Kineta, a clinical-stage biotechnology company focused on novel immunotherapies in oncology, announced the publication of preclinical data on KVA12123 in Frontiers in Immunology. KVA12123 shows strong single-agent anti-tumor activity while minimizing cytokine-related adverse events, recognizing a unique VISTA epitope and binding at neutral and acidic pH. Key results include high affinity binding to VISTA, specificity against VISTA with no cross-reactivity against other B7 family members, and the ability to reverse T cell suppression by myeloid-derived suppressor cells. KVA12123 is currently being evaluated in a Phase 1/2 VISTA-101 open-label clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors (NCT05708950).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.9%
Tags
Kineta, Inc.
Nasdaq:KA
KA Rankings
KA Stock Data
6.44M
6.59M
29.25%
12.05%
0.56%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
MERCER ISLAND
About KA
proteostasis therapeutics is discovering and developing novel small molecule therapeutics designed to control the body’s protein homeostasis, or proteostasis network. the proteostasis network maintains the body’s natural balance of proteins to protect us from numerous diseases. these novel therapies, or proteostasis regulators, are designed to treat multiple genetic and degenerative disorders associated with deficiencies of the proteostasis network, such as alzheimer’s disease, emphysema, huntington’s disease, and type ii diabetes.